The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.

Highlights from the article: We retrospectively reviewed all AML patients treated at City of Hope between June 2016 and April 2019, and identified 8 patients with t-AML and active advanced non-hematological malignancies who received VEN-HMA. All patients were treated with VEN-HMA for newly diagnosed AML except for one who was treated with the combination for r/r AML after failing 2 prior AML therapies. Five patients received concurrent treatment for the underlying non-hematological malignancies, including hormonal therapies, immunotherapy, tyrosine kinase inhibitor and chemotherapy (Table 1). 4 S. Kayser, K. Döhner, J. Krauter, The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML, Blood., 117, 2011, 2137-2145Kayser S, Döhner K, Krauter J, et al.